Clinical Trial

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-11; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-11
Trial Details
NCT Number NCT07028281
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Malignant Solid Tumors
Enrollment 120 participants
Start Date 2025-07-08
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-03